More About Our Business Strategy

Learn About Our Product Pipeline

Advanced Cancer Therapeutics

about advanced cancer therapeutics  

Advanced Cancer Therapeutics (ACT) is leading innovation within the biotechnology industry. Founded in January 2007, the company is focused on the discovery and early development of novel cancer therapeutics as well as selection for partnership, commercialization and manufacture of the most promising discoveries. Utilizing its groundbreaking business arrangement with the James Graham Brown Cancer Center and the University of Louisville Research Foundation, ACT will establish exclusive rights to specific novel therapeutics and fast-track these leading edge discoveries to the pharmaceutical industry, and ultimately the patients who need them.



recent news

Dr. Jason Chesney has been invited to speak at the Targeted Anticancer Therapies (TAT) Conference being held in Washington, D.C. March 21-23, 2016.  
Dr. Chesney will be speaking on PFK-158. The presentation is titled “Phase I Trial of a First-In-Class PFKFB3 Inhibitor Reveals a Novel Immunostimulatory Mechanism of Action.”

Dr. Tapolsky, on behalf of ACT, submitted an abstract for the Annual American Association for Cancer Research (AACR) meeting to be held April 16-20, 2016 in New Orleans.

Dr. Tapolsky submitted an abstract to an AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care. That conference is being held May 12-15, 2016 in Orlando.

Dr. Tapolsky also submitted an abstract to the American Society of Clinical Oncology (ASCO) being held June 3-7, 2016 in Chicago. The topic of the abstract is PFK-158.


As PFK158 has demonstrated to be well tolerated in patients, ACT initiated a dose escalation to cohort 7 with patients already enrolled.


ACT entered into two material transfer agreements (MTA) with two top 20 pharmaceutical companies to evaluate PFK158 in combination with their immunotherapy products in development pipeline and on the market.


ACT is currently conducting a Phase I, open label, dose escalation, multicenter clinical trial in patients with advanced solid tumors. The study is to evaluate the safety, tolerability and antitumor activity of PFK158, a small molecule therapeutic candidate. The centers involved with the study are the MD Anderson Cancer Center in Houston, the University of Texas Health Science Center in San Antonio, the Lombardi Cancer Center at Georgetown
University and the Brown Cancer Center at the University of Louisville.

Learn more about our founders and the management team at Advanced Cancer Therapeutics.

Meet Our Leadership